Swedish researchers discover a blood test that can detect Parkinson's disease up to 20 years before symptoms appear, offering ...

A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson's disease in its earliest stages, before extensive brain damage has ...

More than 1.1 million Americans live with the degenerative brain condition, which can trigger debilitating tremors and effect memory ...

Peer-reviewed Phase 2 Results Inform Ongoing Phase 3/Pivotal Trial of Celeste® in Parkinson’s Disease The Phase 2 study ...

A team led by researchers at Chalmers University of Technology, Sweden, has succeeded in identifying biomarkers for Parkinson ...

Scientists in Sweden and Norway have uncovered a promising way to spot Parkinson’s disease years—possibly decades—before its most damaging symptoms appear. By detecting subtle biological signals in ...

Many more people work very early morning shifts than overnight ones, and a large proportion struggle with excessive sleepiness from shift work disorder, leading to problems with focus, performance and ...

New research reveals how Parkinson's spreads from the gut to the brain, with the help of immune cells—offering a new ...

TRPML1 is a promising target1 for Parkinson’s disease treatments and identifying translational biomarkers will help confirm target engagement ...

ABLi Therapeutics ("ABLi"), a biotechnology company developing therapeutics to address diseases that are associated with activation of Abelson Tyrosine Kinases (c-Abl kinases), announces it has ...

Annovis is also seeking fresh capital while working to advance trials for both Alzheimer's and Parkinson's disease drugs.

ClearPoint Neuro is positioned for robust growth in 2026, driven by IRRAS, the PRISM 1.5T system clearance, and the company's new CRO facility. While the immediate future of uniQure's AMT-130 remains ...